High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status
Posted inDiabetes & Endocrinology Infectious Diseases news Public Health

High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status

A secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines significantly reduce cardiorespiratory and influenza-related hospitalizations in adults aged 65 and older, with consistent benefits observed in patients with diabetes, particularly those with a disease duration exceeding five years.
Six Months of Intermittent Fasting: Potent Lipid Lowering but Limited Impact on Vascular and Glycemic Markers
Posted inCardiology Diabetes & Endocrinology news

Six Months of Intermittent Fasting: Potent Lipid Lowering but Limited Impact on Vascular and Glycemic Markers

A randomized controlled trial investigates the 6-month effects of intermittent fasting on overweight adults, revealing significant improvements in lipid profiles and body composition despite neutral effects on blood pressure and glucose metabolism, alongside novel transcriptomic insights into GLP-1 signaling.
Pre-Meal Whey Protein: A Targeted Nutritional Intervention to Mitigate Postprandial Hyperglycemia in Gestational Diabetes
Posted inDiabetes & Endocrinology news OB/GYN & Women’s Health

Pre-Meal Whey Protein: A Targeted Nutritional Intervention to Mitigate Postprandial Hyperglycemia in Gestational Diabetes

A randomized controlled trial demonstrates that a 20g whey protein pre-load 30 minutes before breakfast significantly reduces postprandial glucose excursions and glycemic variability in women with gestational diabetes throughout the third trimester, offering a promising non-pharmacological management strategy.
Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial
Posted inCardiology Diabetes & Endocrinology news

Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial

The ABILITY Diabetes Global trial demonstrates that the Abluminus DES+ sirolimus-eluting stent failed to meet non-inferiority compared to the XIENCE everolimus-eluting stent in patients with diabetes, showing significantly higher rates of target-lesion failure and revascularization at 12 months.
Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF
Posted inCardiology Diabetes & Endocrinology news

Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF

This analysis of the Phase 3 ARISE-HF trial explores sex differences in diabetic cardiomyopathy (DbCM) and the efficacy of AT-001. While women presented with worse exercise capacity and health status at baseline, the novel aldose reductase inhibitor AT-001 showed consistent safety and efficacy across both sexes.
Metformin Mitigates Betamethasone-Induced Glycemic Dysregulation and Reduces Neonatal Hypoglycemia: Insights from a Randomized Clinical Trial
Posted inDiabetes & Endocrinology news

Metformin Mitigates Betamethasone-Induced Glycemic Dysregulation and Reduces Neonatal Hypoglycemia: Insights from a Randomized Clinical Trial

A multicenter randomized trial demonstrates that prophylactic metformin administration after antenatal betamethasone significantly improves maternal glycemic control and halves the risk of neonatal hypoglycemia in preterm infants, offering a safe intervention for a long-standing clinical challenge.
Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism
Posted inDiabetes & Endocrinology Gastroenterology news

Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism

The 24-week results of the IMPACT trial show that pemvidutide significantly improves MASH resolution without worsening fibrosis. While fibrosis improvement did not reach significance at this early time point, the drug's safety profile and metabolic efficacy mark a significant step forward in hepatology.